GSK taps Omnicom's PHD as media agency of record

Share this article:

GlaxoSmithKline tapped Omnicom's PHD as media agency of record on all of its healthcare products, ousting incumbent WPP's MediaCom.

The Omnicom media agency will handle media planning and buying for OTC and prescription products with exception to Boniva, which GSK co-promotes with Genentech.

“PHD offered the most balance of strategic planning excellence and executional creativity and buying leverage to deliver efficiency and quality, and they're an innovator in the digital media space,” said a GSK spokesperson.

Advertising Age reported that Havas' MPG and Publicis' Starcom were also-rans in the review as well.

Separately, the company has just completed round two of an agency review for all of its US prescription drug advertising. The shortlist, such as it is, is comprised of 20 agencies, and a decision is expected on that early in the new year. Interpublic Group healthcare shops currently handle most of that business. 

Meanwhile, Pfizer announced it was retaining Aegis Group's Carat for media planning and buying following a review. "We are pleased to continue our nearly 11-year relationship with Carat as its agency of record for direct-to-consumer media planning and buying for the pharmaceutical business across all communications channels, and for TV and print buying for the over-the-counter consumer healthcare business in the US," said Ray Kerins, VP external affairs and worldwide communications at Pfizer. "This follows a routine review to ensure Pfizer retains the services that best fits the needs of its business."

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.